AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22278649 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity stretch home mechanical therapy (n = 11)
Number of subjects: 20
Study 22278649 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity stretch home mechanical therapy (n = 9)
Number of subjects: 20
Study 20194929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance with a nonstimulating catheter
Number of subjects: 40
Study 20194929 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation (ES) with a stimulating catheter
Number of subjects: 40
Study 17919698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheath group (n = 49) using Disposable Slide‐On sheaths and CST‐2000 Flexible Cystoscope System
Number of subjects: 100
Study 17919698 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 21) using standard 16F flexible cystoscope with Rapicide
Number of subjects: 100
Study 17919698 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 27) using standard 16F flexible cystoscope with Cidex OPA
Number of subjects: 100
Study 17919698 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 17919698 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 15198451 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological examination (focused neurological examination)
Number of subjects: 48
Study 15198451 — intervention group
Group type: EXPERIMENTAL
Intervention: Three step motor sequencing and horizontal visual tracking tests
Number of subjects: 48
Study 15198451 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without PVWD)
Number of subjects: 48
Study 12586131 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin bolus (500 mg)
Number of subjects: 50
Study 12586131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidin (500 mg loading dose)
Number of subjects: 50
Study 12586131 — intervention group
Group type: COMPARATOR
Intervention: PFA-100
Number of subjects: 50
Study 12586131 — intervention group
Group type: COMPARATOR
Intervention: Aggregometry
Number of subjects: 50
Study 9501951 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 18
Study 9501951 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 18
Study 9501951 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 18
Study 7653794 — intervention group
Group type: COMPARATOR
Intervention: Standard PA catheter with intermittent SvO2 and CO measurements (6 times a day)
Number of subjects: 30
Study 7653794 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous SvO2 monitoring using a fiberoptic PA catheter
Number of subjects: 30
Study 7653794 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous CO monitoring using a newly developed PA catheter
Number of subjects: 30
Study 2719237 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory minute volume (MMV) weaning
Number of subjects: 40
Study 2719237 — intervention group
Group type: COMPARATOR
Intervention: Intermittent mandatory ventilation (IMV)
Number of subjects: 40
Study 367795 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (0.5 g X 4 for 3 days)
Number of subjects: 30
Study 367795 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (0.5 g X 4 for 3 days)
Number of subjects: 30
Study 367795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 367795 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Paracetamol, Acetylsalicylic acid, Placebo)
Number of subjects: 30
Study 31606939 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous NB‐UVB therapy (Side A)
Number of subjects: 23
Study 31606939 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted NB‐UVB therapy (Side B)
Number of subjects: 23
Study 31606939 — intervention group
Group type: COMPARATOR
Intervention: Continuous NB‐UVB treatment (Group 2)
Number of subjects: 23
Study 31606939 — intervention group
Group type: COMPARATOR
Intervention: Interrupted NB‐UVB treatment (Group 3)
Number of subjects: 23
Study 30096700 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy increased avocado added (AA)
Number of subjects: 26
Study 30096700 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoenergic avocado inclusive (AI)
Number of subjects: 26
Study 30096700 — intervention group
Group type: COMPARATOR
Intervention: Avocado-free control (C)
Number of subjects: 26
Study 27189212 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan dosing regimen
Number of subjects: 64
Study 27189212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried Blood Spot (DBS) analysis
Number of subjects: 64
Study 27189212 — intervention group
Group type: COMPARATOR
Intervention: Plasma analysis
Number of subjects: 64
Study 25212693 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 49
Study 25212693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 22170367 — intervention group
Group type: EXPERIMENTAL
Intervention: caffeine (3 mg caffeine/kg)
Number of subjects: 110
Study 22170367 — intervention group
Group type: COMPARATOR
Intervention: decaf (control)
Number of subjects: 110
Study 20619540 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Training Technique (ATT)
Number of subjects: 103
Study 20619540 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 103
Study 17696221 — intervention group
Group type: EXPERIMENTAL
Intervention: Current and emerging therapies for HRS
Number of subjects: 0
Study 15827365 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (1.25 mg/24-h)
Number of subjects: 53
Study 12467854 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (US) assessment of bone status using DBM Sonic 1200
Number of subjects: 54
Study 12467854 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 54
Study 12467854 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate- and high-risk patients
Number of subjects: 54
Study 12467854 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients and controls
Number of subjects: 54
Study 12467854 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 54
Study 12467854 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 54
Study 10540564 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (dry powder with ISF system) 12 mcg twice daily
Number of subjects: 160
Study 10540564 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (200 mg qid)
Number of subjects: 160
Study 8535647 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine (SASP)
Number of subjects: 0
Study 8535647 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination studies and meta-analyses
Number of subjects: 0
Study 2147582 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitumor B (Chinese herbs)
Number of subjects: 9633
Study 2147582 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinamide
Number of subjects: 9633
Study 2147582 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin
Number of subjects: 9633
Study 2147582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9633
Study 7032291 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg every 6 hours)
Number of subjects: 15
Study 7032291 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg every 6 hours)
Number of subjects: 15
Study 7032291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31060099 — intervention group
Group type: EXPERIMENTAL
Intervention: Static CAIS
Number of subjects: 60
Study 31060099 — intervention group
Group type: COMPARATOR
Intervention: Dynamic CAIS
Number of subjects: 60
Study 28741044 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine (5-10 mg/day)
Number of subjects: 51
Study 28741044 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (5-10 mg/day)
Number of subjects: 51
Study 28741044 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 51
Study 28741044 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 51
Study 26381400 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-hour training program on MUPS communication skills
Number of subjects: 123
Study 26381400 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained doctors)
Number of subjects: 123
Study 26381400 — intervention group
Group type: EXPERIMENTAL
Intervention: Training evaluation
Number of subjects: 123
Study 24583541 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV-50 Hz [high amplitude]
Number of subjects: 17
Study 24583541 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV-30 Hz [low amplitude]
Number of subjects: 17
Study 24583541 — intervention group
Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 17
Study 22260818 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clodronate 1600 mg daily
Number of subjects: 60
Study 22260818 — intervention group
Group type: COMPARATOR
Intervention: Anti‐rheumatic therapy alone
Number of subjects: 60
Study 20122153 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school academic support with additional learning materials
Number of subjects: 214
Study 20122153 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school academic support with additional learning materials and additional kit for girls (uniform and clothes)
Number of subjects: 214
Study 20122153 — intervention group
Group type: COMPARATOR
Intervention: Control group (107 villages from CHAMPION trial)
Number of subjects: 214
Study 17925339 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction intervention (12-week weight reduction followed by 4-week weight stabilization)
Number of subjects: 0
Study 17925339 — intervention group
Group type: COMPARATOR
Intervention: Control group (16-week weight maintenance)
Number of subjects: 0
Study 16330884 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone substitution in GH‐deficient patients
Number of subjects: 26
Study 16330884 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study 12000778 — intervention group
Group type: EXPERIMENTAL
Intervention: DOTS with direct observation by health workers
Number of subjects: 0
Study 12000778 — intervention group
Group type: EXPERIMENTAL
Intervention: DOTS with direct observation by family members
Number of subjects: 0
Study 12000778 — intervention group
Group type: EXPERIMENTAL
Intervention: DOTS without direct observation (self-administered)
Number of subjects: 0
Study 12000778 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker sub-group
Number of subjects: 0
Study 9798134 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day estrogen matrix patch (Climara) at 0.5 mg/day
Number of subjects: 0
Study 9798134 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day estrogen matrix patch (Climara) at 0.1 mg/day
Number of subjects: 0
Study 9798134 — intervention group
Group type: COMPARATOR
Intervention: 0.625-mg/day oral conjugated equine estrogen
Number of subjects: 0
Study 9798134 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day estrogen patch
Number of subjects: 0
Study 7605184 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (n = 7) for 12 weeks at a mean intensity of 73% HRmax
Number of subjects: 47
Study 7605184 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 47
Study 2193835 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP)
Number of subjects: 50
Study 2193835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6996120 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol 160 - 800 mg
Number of subjects: 25
Study 6996120 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 100 - 500 mg
Number of subjects: 25
Study 30088030 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA (TiN-coated prostheses)
Number of subjects: 140
Study 28148669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty
Number of subjects: 252
Study 28148669 — intervention group
Group type: COMPARATOR
Intervention: Cemented total hip arthroplasty (THA)
Number of subjects: 252
Study 25458336 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercisers (≥150min of exercise/week)
Number of subjects: 1281
Study 25458336 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercisers
Number of subjects: 1281
Study 25458336 — intervention group
Group type: COMPARATOR
Intervention: Non-exercisers
Number of subjects: 1281
Study 23052798 — intervention group
Group type: EXPERIMENTAL
Intervention: Dunhill operation (DO)
Number of subjects: 200
Study 23052798 — intervention group
Group type: COMPARATOR
Intervention: Bilateral subtotal resection (BST)
Number of subjects: 200
Study 21820543 — intervention group
Group type: EXPERIMENTAL
Intervention: Step It exercise programme plus standard care
Number of subjects: 42
Study 21820543 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 42
Study 19474735 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMP test for pitch direction discrimination
Number of subjects: 42
Study 19474735 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMP test for melody recognition
Number of subjects: 42
Study 19474735 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMP test for timbre recognition
Number of subjects: 42
Study 19474735 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability for pitch
Number of subjects: 42
Study 19474735 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability for melody
Number of subjects: 42
Study 19474735 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability for timbre
Number of subjects: 42
Study 17644623 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak exercise capacity (measured in METs)
Number of subjects: 5145
Study 17644623 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 5145
Study 17644623 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference and BMI
Number of subjects: 5145
Study 17644623 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of diabetes
Number of subjects: 5145
Study 17644623 — intervention group
Group type: EXPERIMENTAL
Intervention: A1C levels
Number of subjects: 5145
Study 17644623 — intervention group
Group type: EXPERIMENTAL
Intervention: History of cardiovascular disease
Number of subjects: 5145
Study 17644623 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 5145
Study 17644623 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker use
Number of subjects: 5145
Study 17644623 — intervention group
Group type: EXPERIMENTAL
Intervention: Race/Ethnicity
Number of subjects: 5145
Study 17644623 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension and diabetes medications (in women)
Number of subjects: 5145
Study 16824835 — intervention group
Group type: COMPARATOR
Intervention: Advanced stethoscope
Number of subjects: 72
Study 16824835 — intervention group
Group type: COMPARATOR
Intervention: Simple stethoscope
Number of subjects: 72
Study 16824835 — intervention group
Group type: COMPARATOR
Intervention: Teaching course
Number of subjects: 72
Study 16824835 — intervention group
Group type: COMPARATOR
Intervention: No teaching course
Number of subjects: 72
Study 16824835 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching for aortic stenosis
Number of subjects: 72
Study 16824835 — intervention group
Group type: COMPARATOR
Intervention: No teaching for aortic stenosis
Number of subjects: 72
Study 16824835 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching for ventricular septum defect
Number of subjects: 72
Study 16824835 — intervention group
Group type: COMPARATOR
Intervention: No teaching for ventricular septum defect
Number of subjects: 72
Study 14533127 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 825
Study 14533127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 825
Study 10979113 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin (3000 mg/d)
Number of subjects: 468
Study 10979113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 8799880 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion
Number of subjects: 10
Study 8799880 — intervention group
Group type: COMPARATOR
Intervention: Placebo (baseline)
Number of subjects: 10
Study 1621412 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrio cholerae El Tor Inaba strain N16961 inoculation of 0.3 x 10(4) c.f.u.
Number of subjects: 26
Study 1621412 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrio cholerae El Tor Inaba strain N16961 inoculation of 1.6 x 10(5) c.f.u.
Number of subjects: 26
Study 1621412 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrio cholerae El Tor Inaba strain N16961 inoculation of 1.9 x 10(6) c.f.u.
Number of subjects: 26
Study 1621412 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrio cholerae El Tor Inaba strain N16961 inoculation of 2.0 x 10(7) c.f.u.
Number of subjects: 26
Study 1621412 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated inoculation of 1.3 x 10(7) c.f.u. of V. cholerae
Number of subjects: 26
Study 1621412 — intervention group
Group type: COMPARATOR
Intervention: Comparison of groups inoculated with different dosages
Number of subjects: 26
Study 6322709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 1,200 mg/day
Number of subjects: 12
Study 6322709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 2,400 mg/day
Number of subjects: 12
Study 6322709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg/day
Number of subjects: 12
Study 6322709 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 12
Study 30875247 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg oral, thrice weekly for 48 weeks)
Number of subjects: 61
Study 30875247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 28025189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopoietic cells delivered endomyocardially with a retention-enhanced catheter (n=120)
Number of subjects: 271
Study 28025189 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (n=151)
Number of subjects: 271
Study 28025189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopoietic cells in patients with baseline left ventricular end-diastolic volume 200-370 mL (60% of patients)
Number of subjects: 271
Study 28025189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopoietic cells (n=120)
Number of subjects: 271
Study 26292180 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony (TGP) 1.8 g/day combined with Methotrexate (MTX) 10 mg/week plus Leflunomide (LEF) 20 mg/day
Number of subjects: 268
Study 26292180 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TGP) with Methotrexate (MTX) 10 mg/week plus Leflunomide (LEF) 20 mg/day
Number of subjects: 268
Study 23599410 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-bonded polysulfone dialyzers
Number of subjects: 0
Study 23599410 — intervention group
Group type: COMPARATOR
Intervention: Polysulfone control group
Number of subjects: 0
Study 21535424 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural therapy (CBT) for first-episode psychosis participants (n = 25)
Number of subjects: 40
Study 21535424 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural therapy (CBT) for stable psychosis patients (n = 15)
Number of subjects: 40
Study 18477407 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Number of subjects: 77
Study 18477407 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional PT exercise
Number of subjects: 77
Study 18477407 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 17123219 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific aftercare measures after inpatient therapy
Number of subjects: 0
Study 17123219 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific aftercare measures)
Number of subjects: 0
Study 15597799 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated protein C
Number of subjects: 0
Study 15597799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11392345 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepubertal major depressive disorder (PMDD)
Number of subjects: 100
Study 11392345 — intervention group
Group type: COMPARATOR
Intervention: Normal comparison (NC) group
Number of subjects: 100
Study 9427854 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 31
Study 9427854 — intervention group
Group type: COMPARATOR
Intervention: CYA
Number of subjects: 31
Study 9427854 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FK506 and CYA
Number of subjects: 31
Study 8387177 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin and cisplatin
Number of subjects: 0
Study 8387177 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin, vindesine, and cisplatin
Number of subjects: 0
Study 8387177 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant MVP (mitomycin, vindesine/vinblastine, higher-dose cisplatin)
Number of subjects: 0
Study 8387177 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone preceding mitomycin
Number of subjects: 0
Study 8387177 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone premedication
Number of subjects: 0
Study 3500381 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily tobramycin (5.1 mg/kg/day for 9 days)
Number of subjects: 20
Study 3500381 — intervention group
Group type: COMPARATOR
Intervention: Thrice daily tobramycin (5.1 mg/kg/day for 9 days)
Number of subjects: 20
Study 30977094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 105
Study 29095725 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-Based Cognitive Behavior Therapy (iCBT) for tinnitus over 8 weeks
Number of subjects: 146
Study 29095725 — intervention group
Group type: COMPARATOR
Intervention: Weekly monitoring (control group)
Number of subjects: 146
Study 29095725 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided iCBT
Number of subjects: 146